KKR & Co. Inc. (KKR)
After hours:
| Previous close | 92.62 |
| Open | 94.09 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 900 |
| Day's range | 92.75 - 95.22 |
| 52-week range | 47.79 - 103.48 |
| Volume | |
| Avg. volume | 3,692,640 |
| Market cap | 84.028B |
| Beta (5Y monthly) | 1.62 |
| PE ratio (TTM) | 23.10 |
| EPS (TTM) | 4.09 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | 0.66 (0.70%) |
| Ex-dividend date | 15 Feb 2024 |
| 1y target est | 117.85 |
- Business Wire
KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma
STOCKHOLM & LONDON, April 23, 2024--Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
ZacksKKR & Co. Inc. (KKR) Rises Higher Than Market: Key Facts
In the most recent trading session, KKR & Co. Inc. (KKR) closed at $94.47, indicating a +2% shift from the previous trading day.
Business WireKKR & Co. Inc. to Announce First Quarter 2024 Results
NEW YORK, April 17, 2024--KKR & Co. Inc. (NYSE: KKR) announced today that it plans to release its financial results for the first quarter 2024 on Wednesday, May 1, 2024, before the opening of trading on the New York Stock Exchange.
